Research article · 6 Oct 2026
Conference abstractPublished 18 Sep 2017
Design of a Cooling TRPM8 agonist to treat ocular discomfort
University of California, USA; Orinda Pharma, Inc, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Ocular discomfort is common because the eye surface has a high density of sensory nerve endings. Current methods for rapid ( 2 hr) relief of symptoms such as irritation, dryness, asthenopia, pruritus, and pain are limited. Physical cooling of the eye surface relieves ocular discomfort, but translating this event to drug treatment has not been much studied. TRPM8, an ion channel target on nerve endings, is associated with sensations of cooling and cold and was chosen here as drug target for screening lead candidates. The agonists called 1-dialkylphosphorylalkanes (Dapa) were chosen as the best source of prototypes by contrast to e.g. icilin, p-menthane carboxamides, p-menthane esters. In the design of an ideal agent, the goals are to select the correct target, and to deliver the right molecule to the right place at the right time. Dense TRPM8 innervation was found on the mouse eyelid and cornea, but not on the conjunctiva. The eyelid receptors were selected as drug targets. Lead candidates potently and selectively activate TRPM8 (linked to cooling) but not TRPV1 or TRPA1 (linked to nociception). A prototype Dapa called cryosim-3 (C3) was tested in subjects with mild forms of dry eye disease (BMC Ophthalmology 2107). C3 applied to upper eyelids (n=30) elicited cooling sensations, lasting 46 min and increased tear secretion. C3, 2 mg/mL in water, or water in a single-unit dispenser was applied 4x times daily for 2 weeks (n=20 per group) and data analyzed before and at 1 and 2 weeks thereafter. In questionnaire surveys of ocular discomfort indices (VAS scale, OSDI, and CVS symptoms), the C3 treatment group clearly showed improvement of symptoms at one and two weeks and an increase of basal tear secretion. No signs of irritation or pain were reported. C3 is a promising candidate for relief of ocular discomfort.
Subjects
Ophthalmology & OptometryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Experimental Ophthalmology.
Short communication · 30 Aug 2026
Vision Science in the Modern Era: Integrating Neuroscience, Genetics, and Technology
Commentary · 3 Aug 2026
Emerging Frontiers in Experimental Ophthalmology: Innovations and Translational Challenges
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Experimental Ophthalmology
- SubjectOphthalmology & Optometry
- BylineArticles whose byline prints “Edward T Wei”
